Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?

Pediatric Clinics of North America

Volumn 55, Issue 1, 2008, Pages 147-167

  Fry, Terry J ^a   Lankester, Arjan C ^b  

^a Center for Cancer and Blood Disorders   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; METHYLTRANSFERASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CELL THERAPY; CHILDHOOD CANCER; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPHOCYTE MIGRATION; NATURAL KILLER CELL; NONHUMAN; RELAPSE; REMISSION; REVIEW; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CANCER VACCINES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PEDIATRICS;

EID: 38649090690     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2007.10.015     Document Type: Review

References (111)

1. Coley W.B. Sarcoma of the long bones: the diagnosis, treatment and prognosis, with a report of sixty-nine cases. Ann Surg 45 3 (1907) 321-368
2. Brunschwig A. The efficacy of "Coley's Toxin" in the treatment of sarcoma: an experimental study. Ann Surg 109 1 (1939) 109-113
3. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 2 (2004) 137-148
4. Matzinger P. An innate sense of danger. Ann N Y Acad Sci 961 (2002) 341-342
5. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
6. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 8 (2006) 595-601
7. Fry T.J., and Mackall C.L. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 174 11 (2005) 6571-6576
8. Rosenberg S.A., Sportes C., Ahmadzadeh M., et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (1997) 29 3 (2006) 313-319
9. Langer L.F., Clay T.M., and Morse M.A. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 7 8 (2007) 1245-1256
10. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6 4 (2006) 295-307
11. Beyer M., and Schultze J.L. Regulatory T cells in cancer. Blood 108 3 (2006) 804-811
12. Banham A.H., Powrie F.M., and Suri-Payer E. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur J Immunol 36 11 (2006) 2832-2836
13. Cooper M.A., Fehniger T.A., and Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 22 11 (2001) 633-640
14. Moretta L., Ferlazzo G., Bottino C., et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 214 (2006) 219-228
15. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16 1 (2006) 3-15
16. Lucas M., Schachterle W., Oberle K., et al. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26 4 (2007) 503-517
17. Degli-Esposti M.A., and Smyth M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 5 2 (2005) 112-124
18. Raulet D.H. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 5 10 (2004) 996-1002
19. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5 3 (2005) 201-214
20. Ljunggren H.G., and Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11 7 (1990) 237-244
21. Bryceson Y.T., March M.E., Ljunggren H.G., et al. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214 (2006) 73-91
22. Hayakawa Y., and Smyth M.J. NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 18 3 (2006) 176-185
23. Pende D., Bottino C., Castriconi R., et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 42 4 (2005) 463-469
24. Castriconi R., Dondero A., Corrias M.V., et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 64 24 (2004) 9180-9184
25. Pende D., Spaggiari G.M., Marcenaro S., et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105 5 (2005) 2066-2073
26. Wu J., and Lanier L.L. Natural killer cells and cancer. Adv Cancer Res 90 (2003) 127-156
27. Becknell B., and Caligiuri M.A. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86 (2005) 209-239
28. Smyth M.J., Cretney E., Kershaw M.H., et al. Cytokines in cancer immunity and immunotherapy. Immunol Rev 202 (2004) 275-293
29. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 5562 (2002) 2097-2100
30. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110 1 (2007) 433-440
31. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12 8 (2006) 876-884
32. Burnett F.M. The concept of immunological surveillance. Prog Exp Tumor Res 13 (1970) 1-27
33. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3 11 (2002) 999-1005
34. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6 10 (2006) 715-727
35. Malmberg K.J., and Ljunggren H.G. Escape from immune- and nonimmune-mediated tumor surveillance. Semin Cancer Biol 16 1 (2006) 16-31
36. Kim R., Emi M., and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121 1 (2007) 1-14
37. Algarra I., Garcia-Lora A., Cabrera T., et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53 10 (2004) 904-910
38. Chang C.C., and Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56 2 (2007) 227-236
39. Lehmann F., Marchand M., Hainaut P., et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25 2 (1995) 340-347
40. Restifo N.P., Marincola F.M., Kawakami Y., et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88 2 (1996) 100-108
41. Seliger B., Cabrera T., Garrido F., et al. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12 1 (2002) 3-13
42. van Hall T., Wolpert E.Z., van Veelen P., et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12 4 (2006) 417-424
43. van den Elsen P.J., Gobin S.J., van Eggermond M.C., et al. Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics 48 3 (1998) 208-221
44. van den Elsen P.J., Holling T.M., van der Stoep N., et al. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. Clin Immunol 109 1 (2003) 46-52
45. Ohnmacht G.A., and Marincola F.M. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. J Cell Physiol 182 3 (2000) 332-338
46. Yee C., Thompson J.A., Byrd D., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99 25 (2002) 16168-16173
47. Meklat F., Li Z., Wang Z., et al. Cancer-testis antigens in haematological malignancies. Br J Haematol 136 6 (2007) 769-776
48. Oppenheim D.E., Roberts S.J., Clarke S.L., et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6 9 (2005) 928-937
49. Fauriat C., Just-Landi S., Mallet F., et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109 1 (2007) 323-330
50. Gonzalez S., Groh V., and Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298 (2006) 121-138
51. Menier C., Riteau B., Carosella E.D., et al. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 100 1 (2002) 63-70
52. Malmberg K.J., Levitsky V., Norell H., et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110 10 (2002) 1515-1523
53. Bladergroen B.A., Meijer C.J., ten Berge R.L., et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood 99 1 (2002) 232-237
54. van Houdt I.S., Oudejans J.J., van den Eertwegh A.J., et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 11 17 (2005) 6400-6407
55. Harada K., Toyooka S., Shivapurkar N., et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62 20 (2002) 5897-5901
56. Stupack D.G., Teitz T., Potter M.D., et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439 7072 (2006) 95-99
57. Ugurel S., Rappl G., Tilgen W., et al. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7 5 (2001) 1282-1286
58. Roth W., Isenmann S., Nakamura M., et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61 6 (2001) 2759-2765
59. Gronbaek K., Straten P.T., Ralfkiaer E., et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92 9 (1998) 3018-3024
60. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16 1 (2006) 38-52
61. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 9 (2004) 942-949
62. Serafini P., Borrello I., and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16 1 (2006) 53-65
63. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4 9 (2004) 675-687
64. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 5795 (2006) 1960-1964
65. Sato E., Olson S.H., Ahn J., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102 51 (2005) 18538-18543
66. Piersma S.J., Jordanova E.S., van Poelgeest M.I., et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67 1 (2007) 354-361
67. von Andrian U.H., and Mempel T.R. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 3 11 (2003) 867-878
68. Chen Q., Wang W.C., and Evans S.S. Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 52 11 (2003) 670-679
69. Carriere V., Colisson R., Jiguet-Jiglaire C., et al. Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res 65 24 (2005) 11639-11648
70. Fisher D.T., Chen Q., Appenheimer M.M., et al. Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol Invest 35 3-4 (2006) 251-277
71. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 2 (2000) 121-127
72. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 4 7 (2004) 540-550
73. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
74. Mapara M.Y., and Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22 6 (2004) 1136-1151
75. June C.H. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117 6 (2007) 1466-1476
76. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 5594 (2002) 850-854
77. Gattinoni L., Powell Jr. D.J., Rosenberg S.A., et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6 5 (2006) 383-393
78. June C.H. Principles of adoptive T cell cancer therapy. J Clin Invest 117 5 (2007) 1204-1212
79. Berger C., Berger M., Feng J., et al. Genetic modification of T cells for immunotherapy. Expert Opin Biol Ther 7 8 (2007) 1167-1182
80. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 5796 (2006) 126-129
81. Dotti G., and Heslop H.E. Current status of genetic modification of T cells for cancer treatment. Cytotherapy 7 3 (2005) 262-272
82. Savoldo B., Goss J.A., Hammer M.M., et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108 9 (2006) 2942-2949
83. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 4 (2005) 296-306
84. Figdor C.G., de Vries I.J., Lesterhuis W.J., et al. Dendritic cell immunotherapy: mapping the way. Nat Med 10 5 (2004) 475-480
85. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 9 (2004) 909-915
86. Paulos C.M., Kaiser A., Wrzesinski C., et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13 18 (2007) 5280-5289
87. Krieg A.M. Development of TLR9 agonists for cancer therapy. J Clin Invest 117 5 (2007) 1184-1194
88. Schlom J., Arlen P.M., and Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13 13 (2007) 3776-3782
89. Dagher R., Long L.M., Read E.J., et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 38 3 (2002) 158-164
90. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61 23 (2001) 8513-8519
91. Rousseau R.F., and Brenner M.K. Vaccine therapies for pediatric malignancies. Cancer J 11 4 (2005) 331-339
92. Rousseau R.F., Haight A.E., Hirschmann-Jax C., et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101 5 (2003) 1718-1726
93. Nash R.A., and Storb R. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr Opin Immunol 8 5 (1996) 674-680
94. Gilleece M.H., and Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma 44 1 (2003) 23-28
95. Hahn T., Wall D., Camitta B., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 11 11 (2005) 823-861
96. Cardoso A.A., Schultze J.L., Boussiotis V.A., et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 88 1 (1996) 41-48
97. Bleakley M., and Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 4 5 (2004) 371-380
98. Molldrem J.J. Vaccinating transplant recipients. Nat Med 11 11 (2005) 1162-1163
99. Rousseau R.F., Biagi E., Dutour A., et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 107 4 (2006) 1332-1341
100. Amrolia P.J., Muccioli-Casadei G., Yvon E., et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102 6 (2003) 2292-2299
101. Solomon S.R., Mielke S., Savani B.N., et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106 3 (2005) 1123-1129
102. Mielke S., Nunes R., Rezvani K., et al. A clinical scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood (2007) [epub ahead of print]
103. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 23 (1985) 1485-1492
104. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 7 (1999) 2105-2116
105. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 8 (2005) 3051-3057
106. Passweg J.R., Koehl U., Uharek L., et al. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 19 4 (2006) 811-824
107. Klingemann H.G. Natural killer cell-based immunotherapeutic strategies. Cytotherapy 7 1 (2005) 16-22
108. Ljunggren H.G., and Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7 5 (2007) 329-339
109. Wayne A.S., Kreitman R.J., and Pastan I. Monoclonal antibodies and immunotoxins as new therapeutic agents for childhood acute lymphoblastic leukemia. American Society of Clinical Oncology 2007 Educational Book (2007), ASCO, Alexandria (VA) p. 596-601
110. Pastan I., Hassan R., Fitzgerald D.J., et al. Immunotoxin therapy of cancer. Nat Rev Cancer 6 7 (2006) 559-565
111. Boerman O.C., Koppe M.J., Postema E.J., et al. Radionuclide therapy of cancer with radiolabeled antibodies. Anticancer Agents Med Chem 7 3 (2007) 335-343